|
|
|
|
TUSTIN--- Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer |
| 6/30/2008 @ 6:47 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC). The primary objective of the study is to assess the overall response rate to the combination of bavituximab with a standard regimen of carboplatin and paclitaxel in NSCLC patients. The multi-center clinical trial is being conducted in India.
"The initiation of patient enrollment and dosing in our trial of bavituximab in combination with chemotherapy in lung cancer patients marks an important milestone in our Phase II bavituximab clinical program," said Steven W. King, president and CEO of Peregrine. "We are eager to test the combination of bavituximab with carboplatin and paclitaxel in these patients, since 50% of advanced cancer patients treated with this combination in our Phase Ib trial achieved an objective tumor response. We look forward to learning more about bavituximab's potential in NSCLC, an important new indication that is a leading cause of cancer deaths for both men and women."
In the trial's two-stage design, up to 21 patients with NSCLC will be enrolled initially. The study will then be expanded up to a total of 49 patients if promising results are observed in the initial cohort. Secondary objectives of the study include time to tumor progression, duration of response, overall patient survival and safety parameters. Tumor response in the study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. Patients may continue to receive bavituximab as long as the cancer does not progress and side effects are acceptable.
The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.
Lung cancer is a major cause of cancer deaths worldwide. According to the American Cancer Society, in the U.S. lung cancer is the second most commonly diagnosed cancer in men and women and is the leading cause of cancer deaths. It estimates that in the U.S. in 2008, there will be approximately 215,400 new cases of lung cancer and an estimated 161,800 lung cancer deaths. Non-small cell lung cancer, or NSCLC, is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases.
Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in Phase II combination therapy trials for the treatment of advanced breast cancer and non-small cell lung cancer and a second Phase II trial in breast cancer is expected to begin soon. In a Phase Ib trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A Phase I bavituximab monotherapy trial in advanced solid cancers is continuing.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara . Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com/), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com/. |
| Orange County |
|
|
| |
| Friday, August 29, 2008 |
 |
|
IRVINE--- Broadcom Announces New Digital Television Solution Supporting Global Connectivity Posted 3:18 PM PST
IRVINE--- ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008 Posted 8:34 AM PST
IRVINE--- Epicor Opens First Office in Thailand; Expands Operations in Asia Pacific Region Posted 8:22 AM PST
|
| |
| Thursday, August 28, 2008 |
|
|
ALISO VIEJO--- Valeant Pharmaceuticals and GlaxoSmithKline Announce Worldwide Collaboration Agreement for Retigabine Posted 7:48 AM PST
IRVINE--- CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement Posted 7:44 AM PST
|
| |
| Wednesday, August 27, 2008 |
|
|
IRVINE--- From the Data Center to the Shop Floor: ATEN Technology New 3-in-1 Serial Device Server Supports RS-232, RS-422 and RS-485 Data Transfers Posted 3:52 PM PST
IRVINE--- Samsung Introduces New Line of Innovative LCD Digital Photo Frames Posted 3:23 PM PST
COSTA MESA--- Irvine Sensors Announces Reverse Stock Split to be Effective Before Open of Market Today Posted 9:12 AM PST
ANAHEIM--- MFLEX Announces Expansion Satellite Facility in Malaysia Posted 9:09 AM PST
WESTMINSTER--- Noran Engineering, Inc. Becomes Nei Software Posted 8:53 AM PST
HUNTINGTON BEACH--- U. S. Market for Artificial Disc Replacement Products to Grow by Over 40% through 2013 Reaching $440 Million Posted 8:52 AM PST
HUNTINGTON BEACH--- U. S. Market for Artificial Disc Replacement Products to Grow by Over 40% through 2013 Reaching $440 Million Posted 8:45 AM PST
|
| |
| Tuesday, August 26, 2008 |
|
|
HUNTINGTON BEACH--- Supplier Market for U.S. Minimally Invasive Aesthetic Products Poised to Grow from $1.5 Billion in 2007 to Nearly $2.5 Billion by 2016 Posted 3:27 PM PST
IRVINE--- Alsius Corporation Receives 510(K) Market Clearance for Solex Catheter Posted 8:54 AM PST
IRVINE--- Linksys Helps Make Home Networking Greener; Eco-Friendlier Packaging and ENERGY STAR Certified Power Adapters Help Set Standards for Home Networking Products Posted 8:48 AM PST
IRVINE--- Aluratek Debuts Tornado plus External Hard Drives with RFID Security Key Data Encryption Onboard Posted 8:01 AM PST
|
| |
| Monday, August 25, 2008 |
|
|
IRVINE--- IOGEAR Introduces Industry-First KVM Switch Enabling Control of a Second Computer With a Laptop Posted 6:33 AM PST
IRVINE--- VLSystems Achieves Cisco Master Security Specialization in United States Posted 6:29 AM PST
ORANGE--- Elephant Talk's Management and Insiders Add Another $6.3M to Company's Capital Account, With an Additional $1M Posted 6:27 AM PST
ORANGE COUNTY-- Beckman Coulter to Present at the Morgan Stanley Healthcare Unplugged Conference Posted 6:26 AM PST
NEWPORT BEACH--- Conexant’s DSL Technology Powers ZTE’s Next-Generation DSLAMS Posted 6:20 AM PST
COSTA MESA--- Oxygen Biotherapeutics, Inc. to Meet With FDA to Discuss Proposed Phase II-b Oxycyte Clinical Trial Posted 6:18 AM PST
IRVINE--- Integrien Joins the Vmware Technology Alliance Partner Program Posted 6:17 AM PST
IRVINE--- BioLargo Enters into Marketing Agreement for Leading Iodine Disinfection Technology Posted 6:16 AM PST
|
| |
| Friday, August 22, 2008 |
|
|
IRVINE--- Endocare and Former CFO Agree to Terminate Indemnification Agreement Posted 3:34 PM PST
|
| |
| Thursday, August 21, 2008 |
|
|
IRVINE--- Ensynch Names Stan Lequin Chief Operating Officer Posted 3:58 PM PST
LAKE FOREST--- I-Flow Corporation Announces Award of Multi-year Contract for ON-Q by HealthTrust Purchasing Group Posted 8:38 AM PST
BUENA PARK--- Yamaha Ships Disklavier Mark IV Version 3.0 Posted 8:37 AM PST
COSTA MESA--- SYSPRO Delivers Enhanced Integration Via the 2007 Microsoft Office Fluent User Interface Posted 8:33 AM PST
|
| |
| Wednesday, August 20, 2008 |
|
|
MANASSAS, VA--- Lockheed Martin Awarded $5.8M Contract to Maintain Pentagon Electronic Messaging Systems Posted 6:11 PM PST
IRVINE-- - Quantum Announces $19.1 Million in Registered Direct Offering of Common Stock With a Single Institutional Investor Posted 6:10 PM PST
NEWPORT BEACH--- Azz Technologies Announces That Tower Semiconductor Has Signed Memorandum of Understanding to Restructure Tower’s Debt Posted 5:43 AM PST
|
| |
| Tuesday, August 19, 2008 |
|
|
ALISO VIEJO--- Private Access Appoints Marc Kirshbaum as President & COO Posted 3:05 PM PST
IRVINE--- Pharmacogenomics Pioneer HairDX Names David Teckman President and CEO Posted 2:47 PM PST
IRVINE--- Hop-on Announces New US Distributor for NFL Games in the Midwest Posted 8:11 AM PST
IRVINE--- ChinaTel Group Announces Renewal of Licenses Posted 7:36 AM PST
IRVINE--- Newly Launched GreenUmbrella.comTM Earns McAfee Secure Site Certification Posted 7:35 AM PST
SANTA ANA--- Iteris Selected by LACMTA for Transit Signal Priority Systems Contract Valued at Just Under $8.0 Million Posted 7:34 AM PST
NEWPORT BEACH--- Kirk Kopic Named President at Vimation Posted 7:32 AM PST
HUNTINGTON BEACH--- Pioneering Group of Emerging Medtech Companies Seek $240 Million in New Financing Posted 7:31 AM PST
|
| |
| Monday, August 18, 2008 |
|
|
IRVINE--- Broadcom Announces Leading Single-Chip Cable Set-Top Box Digital-to-Analog Adapter Solution Posted 7:46 AM PST
IRVINE--- JCPenney Names Epicor Retail “Supplier of the Year” Posted 7:00 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
